Momenta Pharmaceuticals Inc MNTA:NASDAQ

Last Price$16.56Cboe Real-Time Last Sale as of 2:30PM ET 11/13/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.11(0.67%)
Bid (Size)$16.57 (100)
Ask (Size)$16.59 (107)
Day Low / High$16.08 - 16.63
Volume320.7 K
 

View Biotechnology IndustryPeer Comparison as of 11/13/2019

 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $16.56
Change: +0.11 (0.67%)
Volume: 320.7 K
2:30PM ET 11/13/2019
 
 

Eidos Therapeutics Inc ( NASDAQ )

Price: $41.80
Change: -1.49 (3.44%)
Volume: 69.1 K
2:30PM ET 11/13/2019
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Insmed Inc ( NASDAQ )

Price: $19.48
Change: +0.49 (2.58%)
Volume: 564.1 K
2:30PM ET 11/13/2019
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $27.60
Change: -0.72 (2.54%)
Volume: 542.6 K
2:30PM ET 11/13/2019
 

Read more news Recent News

Analyst Actions: SunTrust Initiates Coverage on Momenta Pharmaceuticals With Buy Rating, $29 Price Target
8:42AM ET 11/12/2019 MT Newswires

Momenta Pharmaceuticals' (MNTA) average rating among analysts is a buy, with an average price target of $25. Price: 16.00, Change: -0.41, Percent Change:...

Insider Trends: Momenta Pharmaceuticals Insider Disposition Slows 90-Days of Buys
4:17PM ET 11/08/2019 MT Newswires

Dr Santiago Arroyo, SVP, Chief Medical Officer, on Nov 07, 2019, sold 26,954 shares in Momenta Pharmaceuticals (MNTA) for $428,838. The sale of shares of...

Analyst Actions: Wells Fargo Initiates Coverage on Momenta Pharmaceuticals With Outperform Rating
8:23AM ET 11/06/2019 MT Newswires

Momenta Pharmaceuticals' (MNTA) average rating among analysts is a buy, with an average price target of $24. Price: 14.73, Change: -0.32, Percent Change:...

Momenta Pharmaceuticals Posts Narrower Q3 Loss, Revenue Declines Vs Yr Ago -- Shares Down More Than 4%
2:54PM ET 10/31/2019 MT Newswires

Momenta Pharmaceuticals (MNTA) is down more than 4% as the company posted a Q3 loss of $0.45, narrower than the loss of $0.65 in the same period a year...

Company Profile

Business DescriptionMomenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. View company web site for more details
Address301 Binney Street
Cambridge, Massachusetts 02142
Phone+1.617.491.9700
Number of Employees131
Recent SEC Filing11/12/20194
President, Chief Executive Officer & DirectorCraig A. Wheeler
Treasurer, Chief Financial & Accounting OfficerMichelle Robertson
Chief Scientific OfficerAnthony M. Manning
Chief Medical Officer & Senior VP-DevelopmentSantiago Arroyo

Company Highlights

Price Open$16.35
Previous Close$16.45
52 Week Range$9.51 - 16.90
Market Capitalization$1.6 B
Shares Outstanding98.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/28/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.14
Beta vs. S&P 500N/A
Revenue$75.6 M
Net Profit Margin-361.66%
Return on Equity-57.49%

Analyst Ratings as of 11/11/2019

Buy
5
Overweight
0
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset